ALVO
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$5.87
+9.93%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.45
From 52W high−34.63%
Volume3.42M
Market cap$2.09B
P/E (TTM)—
P/S (TTM)4.3x
Div yield—
Key dataSep 18, 2026
Open
$5.45
From 52W high
−34.63%
Volume
3.42M
Market cap
$2.09B
ValuationView details →
P/E (Fwd)
39.6x
EV/EBITDA
−2388.5x
P/E (TTM)
—
RSI (14)
74.4
MomentumView details →
1D Return
+9.93%
YTD Return
+14.33%
SummaryUpdated Jun 1, 2026
Alvotech (NASDAQ:ALVO) is an Iceland-based biotechnology company founded in 2013 that specializes in developing and manufacturing biosimilar medicines. The company went public in June 2022 and has invested approximately $2 billion over more than a decade to build a vertically integrated biosimilar platform. Alvotech operates globally with commercial reach extending to over 90 countries and maintains its headquarters in Reykjavik, Iceland, with additional operations including recent acquisitions in Sweden.
Similar companies
Latest newsMore news →
Fuji Pharma obtained manufacturing and marketing approval in Japan for two biosimilar products, ustekinumab BS 130mg intravenous infusion and golimumab BS 50mg subcutaneous autoinjector.2d agoAlvotech shares rose 5.58% to $5.30 in after-hours trading on September 16, 2026, ahead of an FDA review decision.4d agoAlvotech announced its financial results for the first half of 2026 and provided a business update on August 19, 2026.32d ago